TRANSGENE (ENX:TNG) Announces Plans For A Phase 1b/2 Trial With Pexa-Vec In Advanced Solid Tumors
2/25/2014 9:20:52 AM
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced plans for a Phase 1b/2 trial with Pexa-Vec that is to be funded by the Institut National du Cancer (INCa). This trial will be part of an INCa-funded program called CLIP², that is facilitating patient access to innovative treatments and promoting global exchanges in cutting edge research that involve academic-initiated research and novel therapies being developed by biotechnology and pharmaceutical companies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by